Michael Chi Sells 7,500 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 7,500 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $26.00, for a total value of $195,000.00. Following the completion of the transaction, the insider now owns 193,601 shares in the company, valued at approximately $5,033,626. The trade was a 3.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Michael Chi also recently made the following trade(s):

• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24.
• On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.00, for a total transaction of $380,688.00.
• On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00.

Hims & Hers Health Stock Up 5.3 %

Hims & Hers Health stock traded up $1.40 during trading on Monday, hitting $27.60. The stock had a trading volume of 10,968,314 shares, compared to its average volume of 10,082,213. The stock’s 50 day moving average is $25.78 and its two-hundred day moving average is $21.26. Hims & Hers Health, Inc. has a 1 year low of $8.09 and a 1 year high of $35.02. The stock has a market cap of $6.03 billion, a price-to-earnings ratio of 62.73 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the prior year, the company earned ($0.04) EPS. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on HIMS shares. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their price target for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Morgan Stanley initiated coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $22.80.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of HIMS. Renaissance Technologies LLC grew its stake in Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares in the last quarter. State Street Corp grew its position in shares of Hims & Hers Health by 4.7% in the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after purchasing an additional 206,078 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares during the period. Wellington Management Group LLP lifted its holdings in Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after purchasing an additional 218,566 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.